药品详细
Sodium bicarbonate(碳酸氢钠)
化学结构式图
中文名
碳酸氢钠
英文名
Sodium bicarbonate
分子式
CHNaO3
化学名
sodium hydrogen carbonate
分子量
Average: 84.0066
Monoisotopic: 83.982338573
Monoisotopic: 83.982338573
CAS号
144-55-8
ATC分类
B05X 未知;B05C 未知
药物类型
small molecule
阶段
approved
商品名
同义名
基本介绍
Sodium bicarbonate is a white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions.
生产厂家
- Abbott laboratories pharmaceutical products div
- Hospira inc
封装厂家
- Alaven Pharmaceutical
- Alcon Laboratories
- American Regent
- Amphastar Pharmaceuticals
- APP Pharmaceuticals
- A-S Medication Solutions LLC
- Atlantic Biologicals Corporation
- B. Braun Melsungen AG
- C.O. Truxton Inc.
- Cardinal Health
- Claris Lifesciences Inc.
- Concord Labs
- Consolidated Medical Imaging
- Cura Pharmaceutical Co. Inc.
- Dispensing Solutions
- Fresenius Kabi AB
- General Injectables and Vaccines Inc.
- Hospira Inc.
- Humco
- Luitpold Pharmaceuticals Inc.
- Mckesson Corp.
- Mylan
- Norwich Pharmaceuticals Inc.
- Physicians Total Care Inc.
- Prasco Labs
- QOL Medical
- Sandhills Packaging Inc.
- Santarus Inc.
参考
| Synthesis Reference | Not Available |
| General Reference | Not Available |
剂型
规格
化合物类型
| Type | small molecule |
| Classes |
|
| Substructures |
|
适应症
药理
| Indication | Sodium bicarbonate is used for the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturateprotein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments. |
| Pharmacodynamics | Intravenous sodium bicarbonate therapy increases plasma bicarbonate, buffers excess hydrogen ion concentration, raises blood pH and reverses the clinical manifestations of acidosis. |
| Mechanism of action | Sodium bicarbonate is a systemic alkalizer, which increases plasma bicarbonate, buffers excess hydrogen ion concentration, and raises blood pH, thereby reversing the clinical manifestations of acidosis. It is also a urinary alkalizer, increasing the excretion of free bicarbonate ions in the urine, thus effectively raising the urinary pH. By maintaining an alkaline urine, the actual dissolution of uric acid stones may be accomplished. Sodium bicarbonate acts as an antacid and reacts chemically to neutralize or buffer existing quantities of stomach acid but has no direct effect on its output. This action results in increased pH value of stomach contents, thus providing relief of hyperacidity symptoms. [PharmGKB] |
| Absorption | Not Available |
| Volume of distribution | Not Available |
| Protein binding | Not Available |
| Metabolism |
Not Available
|
| Route of elimination | Not Available |
| Half life | Not Available |
| Clearance | Not Available |
| Toxicity | Not Available |
| Affected organisms |
|
| Pathways | Not Available |
理化性质
| Properties | ||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| State | solid | |||||||||||||||||||||||||||||||||||||||
| Experimental Properties |
|
|||||||||||||||||||||||||||||||||||||||
| Predicted Properties |
|
|||||||||||||||||||||||||||||||||||||||
药物相互作用
| Drug | Interaction |
|---|---|
| Atazanavir | This gastric pH modifier decreases the levels/effect of atazanavir |
| Benzphetamine | Alkalinizing agents such as sodium bicarbonate may decrease the excretion of amphetamines like benzphetamine. Increased clinical effects and/or toxicity may occur. Therapy modification should be considered. |
| Deferiprone | Deferiprone may decrease gastrointestinal absorption by chelating to other ions. Interaction is significant so monitor closely. |
| Eltrombopag | Levels of eltrombopag are decreased due to GI inhibition. Separate administration by at least 4 hours. |
| Lithium | The urine alkalizer decreases the effect of lithium |
| Memantine | Possible increased levels of memantine |
| Methenamine mandelate | Urine alkalizer decreases the effect of methenamine |
| Quinidine | The antacid increases the effect of quinidine |
| Ticlopidine | Sodium bicarbonate may decrease Ticlopidine levels. Administer agents 1 to 2 hours apart. |
| Tipranavir | Sodium bicarbonate may decrease the absorption of Tipranavir. Separate administration of the agents and monitor for decreased efficacy of Tipranavir. |
| Trandolapril | Sodium bicarbonate may decrease the absorption of Trandolapril. Administration should be spaced. |
食物相互作用
Not Available
收藏